State Street Corp Acquires 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

State Street Corp increased its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 28.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 951,251 shares of the company’s stock after acquiring an additional 208,344 shares during the quarter. State Street Corp’s holdings in Pyxis Oncology were worth $3,491,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in PYXS. Intech Investment Management LLC bought a new stake in Pyxis Oncology during the third quarter worth approximately $55,000. SG Americas Securities LLC bought a new stake in shares of Pyxis Oncology in the 3rd quarter valued at about $58,000. The Manufacturers Life Insurance Company purchased a new stake in Pyxis Oncology during the second quarter worth $65,000. MetLife Investment Management LLC grew its holdings in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the last quarter. Finally, Schulhoff & Co. Inc. raised its position in shares of Pyxis Oncology by 90.9% in the 2nd quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock valued at $139,000 after purchasing an additional 20,000 shares during the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Trading Down 1.9 %

Shares of Pyxis Oncology stock opened at $1.56 on Tuesday. The company has a fifty day simple moving average of $2.76 and a 200-day simple moving average of $3.22. Pyxis Oncology, Inc. has a 12-month low of $1.49 and a 12-month high of $6.85. The stock has a market cap of $92.77 million, a price-to-earnings ratio of -1.51 and a beta of 1.00.

Analysts Set New Price Targets

Several brokerages have recently issued reports on PYXS. William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Stephens started coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price target on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 price target (down previously from $10.00) on shares of Pyxis Oncology in a report on Friday, December 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price (down previously from $7.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.43.

Insider Buying and Selling

In related news, CFO Pamela Ann Connealy bought 88,850 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were bought at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the transaction, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 9.80% of the stock is currently owned by company insiders.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.